Journal of Endocrinological Investigation

, Volume 7, Issue 2, pp 151–156 | Cite as

Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves’ disease associated with localized myxedema

  • C. A. Hardisty
  • A. Fowles
  • D. S. Munro


When localized myxedema occurs in Graves’ disease, there is often very high serum long acting thyroid stimulator (LATS) activity. However, this association is not invariable and no pathogenetic role for this IgG associated activity is known. Serum LATS protector (LATS-P) is a closely related IgG activity which is present in the majority of cases of untreated Graves’ disease. It usually coexists in LATS positive sera in a substantially greater concentration. Its association with localized myxedema has not been studied, nor have serial studies been performed on this activity during the clinical course of the disease. Fourteen patients (13 females, 1 male) with localized myxedema and a history of Graves’ disease were examined. In 13 serum LATS was detectable with a wide range of activity from 2.4 to 1,000 units/ml. Serum LATS-P was detected in all including the LATS negative patient with a range of activity from 46 to 4,068 units/ml. Serial studies for at least 2 years were conducted in 8 patients. In two there was no change in either skin lesions or in serum LATS and LATS-P. In 6 the skin lesions partially or completely resolved. In 5 this was associated with statistically significant falls in serum LATS and LATS-P but in one no significant change occurred. The study demonstrated the high prevalence of LATS and LATS-P in localized myxedema. I n the sole LATS negative patient there was a high concentration of LATS-P. The role of these activities in the pathogenesis of the disease remains unknown but in serial studies falls in activity were usually associated with clinical improvement.


Long acting thyroid stimulator long acting thyroid stimulator protector pretibial myxedema Graves disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Malkinson R.D. Hyperthyroidism, pretibial myxoedema and clubbing. Arch. Dermatol. 88: 303, 1963.PubMedCrossRefGoogle Scholar
  2. 2.
    Kriss J.P., Pleshakov V., Chein J.R. Isolation and identification of long acting thyroid stimulator and its relation to hyperthyroidism and circumscribed pretibial myxedema. J. Clin. Endocrinol. Metab. 24: 1005, 1964.PubMedCrossRefGoogle Scholar
  3. 3.
    Pinchera A., Pinchera M.G., Stanbury J.B. Thyrotropin and long acting thyroid stimulator assays in thyroid disease. J. Clin. Endocrinol. Metab. 25, 189, 1965.PubMedCrossRefGoogle Scholar
  4. 4.
    Lipman L.M., Green D.E., Snyder N.J., Nelson J.C., Solomon D.H. Relationship of long acting thyroid stimulator to the clinical features and course of Graves’ disease. Am. J. Med. 43: 486, 1967.PubMedCrossRefGoogle Scholar
  5. 5.
    Dirmikis S., Munro D.S. Studies on long acting thyroid stimulator protector in serum containing long acting thyroid stimulator. J. Endocrinol. 64: 29P, 1975 (Abstract).PubMedGoogle Scholar
  6. 6.
    Hardisty C.A., Hanford L., Humphries H., Munro D.S. Long acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis. Clin. Endocrinol. (Oxf.) 14: 631, 1981.CrossRefGoogle Scholar
  7. 7.
    Smith B.R. The interaction of long acting thyroid stimulator with thyroid tissue in vitro.. J. Endocrinol. 46: 45, 1970.PubMedCrossRefGoogle Scholar
  8. 8.
    Dirmikis S. Some factors affecting the detection of long acting thyroid stimulator protector using the McKenzie bioassay. J. Endocrinol. 63: 427, 1974.PubMedCrossRefGoogle Scholar
  9. 9.
    Finney D.J. Statistical method in biological assay. Charles Griffin and Co., Ltd., London, 1964.Google Scholar
  10. 10.
    Schermer D.R., Roeniek H.H., Schumacher O.P., McKenzie J.M. Relationship of long acting thyroid stimulator to pretibial myxoedema. Arch. Dermatol. 102: 62, 1970.PubMedCrossRefGoogle Scholar
  11. 11.
    Samuelsson S.M., Werner I. Long acting thyroid stimulator (LATS) and iodo-amino acids in pretibial myxoedema. Acta Endocrinol. (Kbh.) 59: 409, 1968.Google Scholar
  12. 12.
    From E., Diederichsen H., Haydenreich G., Nielsen O.S. Long acting thyroid stimulator (LATS) and immunofluorescent studies in patients with pretibial myxoedema. Dan. Med. Bull. 20: 188, 1973.PubMedGoogle Scholar
  13. 13.
    Pimstone B.L., Hoffenberg R., Black E. Parallel assay of thyrotropin, long-acting thyroid stimulator and exophthalmos producing substance in endocrine exophthalmos and pretibial myxedema. J. Clin. Endocrinol. Metab. 24: 976, 1964.PubMedCrossRefGoogle Scholar
  14. 14.
    Cheung H.S., Nicoloff J.T., Kamiel M.B., Spolter L., Nimni M.E. Stimulation of fibroblast biosynthetic activity by serum of patients with pretibial myxoedema. J. Invest. Dermatol. 71: 12, 1978.PubMedCrossRefGoogle Scholar
  15. 15.
    Dandona P., Marshall N.J., Bidey S.P., Nathan A., Havard G.D.H. Successful treatment of exophthalmos and pretibial myxoedema with plasmapheresis. Br. Med. J. 7: 374, 1979.CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1984

Authors and Affiliations

  • C. A. Hardisty
    • 1
  • A. Fowles
    • 1
  • D. S. Munro
    • 1
  1. 1.University Department of Medicine, Clinical Sciences CentreNorthern General HospitalSheffieldEngland

Personalised recommendations